Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT: 2009-2024

Historic EBT for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$123.5 million.

  • Myriad Genetics' EBT fell 23.58% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 264.75%. This contributed to the annual value of -$123.5 million for FY2024, which is 52.90% up from last year.
  • Myriad Genetics' EBT amounted to -$123.5 million in FY2024, which was up 52.90% from -$262.2 million recorded in FY2023.
  • In the past 5 years, Myriad Genetics' EBT ranged from a high of -$57.1 million in FY2021 and a low of -$283.6 million during FY2020.
  • Moreover, its 3-year median value for EBT was -$140.6 million (2022), whereas its average is -$175.4 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 18,508.33% in 2020, then skyrocketed by 79.87% in 2021.
  • Myriad Genetics' EBT (Yearly) stood at -$223.3 million in 2020, then reached -$283.6 million in 2020, then soared by 79.87% to -$57.1 million in 2021, then plummeted by 146.23% to -$140.6 million in 2022, then plummeted by 86.49% to -$262.2 million in 2023, then skyrocketed by 52.90% to -$123.5 million in 2024.